Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis ...

The domain wall density decreases with pressure and the domains disappears at modest pressure of 3 GPa. This indicates that the high pressure phase of PMN-PT is not a macroscopic polar state. We ...

SPEEDWAY, Ind. — After a tumultuous Month of May in the Team Penske garage, two-time defending Indy 500 champion Josef Newgarden started from the back row in his attempt at an unprecedented three-peat ...

The race consists of 200 laps around the 2 1/2-mile track at the Indianapolis Motor Speedway for a total of 500 miles ... Ward to become just the sixth driver to win consecutive races. 3. The ...

showed significant improvements in motor function compared to untreated patients with the disease, suggesting the therapy could slow DMD’s progression during a stage when physical decline is typically ...

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of phase 2 meeting. Promontory Therapeutics is moving forward with a ...